T Cell Receptor Gene-Engineered T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid Tumor

Key Inclusion Criteria:

• Age between 18-75 years

• Diagnosis of pathologically or histologically confirmed unresectable or advancedsolid tumor, and have no standard treatment options available or unable to toleratethe currently available standard treatments

• HLA-A11:01positive Tumor has KRAS G12V (NW-301V cohort) or G12D (NW-301D cohort)mutation * Adequate organ function prior to apheresis and lymphodepletingchemotherapy

• ECOG performance status of 0-1

• At least one tumor lesion measurable according to RECIST 1.1 (Additionalprotocol-defined Inclusion criteria may apply.)

Key Exclusion Criteria:

• Received the following treatments: Cytotoxic chemotherapy within 2 weeks prior toapheresis and within 1 week prior to lymphodepletion; Treatment with antibodies (including but not limited to those with monoclonal antibodies and immune checkpointinhibitors) or other biologic therapy within 2 weeks prior to apheresis and within 1week prior to lymphodepletion; Immunosuppressive agents (e.g., calcineurininhibitors, methotrexate or other chemotherapeutic agents, mycophenolate mofetil,rapamycin, thalidomide, immunosuppressive antibodies such as anti-TNF, anti-IL-6, oranti-IL-6 receptor) within 2 weeks prior to apheresis and within 1 week prior tolymphodepletion

• History of allergic reactions to cyclophosphamide, fludarabine, or any otherchemical or biological components of the drugs used in this study

• History of chronic or recurrent severe autoimmune disease, or active immune diseaserequiring treatment with steroids or other immunosuppressive agents within 1 yearprior to enrollment* Have symptomic CNS metastases

• Have leptomeningeal disease or carcinomatous meningitis

• Have ongoing or active infection

• Active infections with HIV, HBV, HCV, or syphilis

• Breastfeeding or pregnant (Additional protocol-defined Exclusion criteria mayapply.)